Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma

Vincenzo Valentini, Francesco Cellini, Vito Lorusso, Alessio Giuseppe Morganti, Nicola Silvestris, Vito Longo, Michele Reni, Alessandro Bittoni, Ivana Cataldo, Stefano Partelli, Massimo Falconi, Aldo Scarpa, Oronzo Brunetti, Daniele Santini, Alessio Morganti, Stefano Cascinu

Risultato della ricerca: Contributo in rivistaArticolo in rivista

26 Citazioni (Scopus)

Abstract

Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.
Lingua originaleEnglish
pagine (da-a)309-324
Numero di pagine16
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume98
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Adenocarcinoma
  • Borderline
  • Carcinoma, Pancreatic Ductal
  • Chemoradiotherapy
  • Chemotherapy
  • Clinical Trials as Topic
  • Geriatrics and Gerontology
  • Hematology
  • Humans
  • Locally advanced
  • Molecular Targeted Therapy
  • Neoadjuvant
  • Neoadjuvant Therapy
  • Oncology
  • Pancreatic Neoplasms
  • Pancreatic ductal adenocarcinoma
  • Radiotherapy
  • Target therapy

Fingerprint Entra nei temi di ricerca di 'Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma'. Insieme formano una fingerprint unica.

Cita questo